Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRESCENT 1: Phase I CYT001 peptide vaccine in unresectable hepatocellular carcinoma
jRCT2031190072Phase 1Suspended
- Sponsor
- CYTLIMIC
- Start
- May 2020
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CYT001 in hepatocellular carcinoma (HCC), sponsored by CYTLIMIC. Primary endpoint: Incidence of dose-limiting toxicities (DLT). Started May 2020; status: suspended.
02
Drugs
CYT001
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031190072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190072.